Skip to main content

Advertisement

SpringerLink
Log in

The Role of Surgery in Management of Locally Advanced Non-Small Cell Lung Cancer

  • Lung Cancer (HA Wakelee, Section Editor)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Patients with locally advanced non-small cell lung cancer (NSCLC) are treated for cure, but treatment decisions are not straightforward. Chemotherapy is essential due to the high risk of systemic relapse, but local therapy is also required for cure. In the small subset of stage III patients with N0 or N1 disease, surgery is typically the initial therapy and extended resections are frequent. The majority of IIIA patients present with N2 disease and treatment paradigms for these patients are controversial, particularly concerning the role of resection. Surgery has a limited role in bulky IIIA, IIIB, and IIIC disease, which is typically treated with combined systemic therapy and radiation. The authors believe that in resectable IIIA disease, the addition of surgery to multimodality treatment appears to improve local control and overall survival. Induction therapy is essential, and the use of chemotherapy alone or chemoradiotherapy remains an area of debate. Pneumonectomy should be used with caution in IIIA disease, as numerous prospective trials have noted excessive perioperative mortality. The introduction of immunotherapies in this stage may quickly transform treatment decisions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.

    Article  Google Scholar 

  2. Howlader N, Noone A, Krapcho M, Miller D, Bishop K, Altekruse S, et al. SEER Cancer statistics review, 1975–2013. Bethesda, MD: National Cancer Institute; 2016.

    Google Scholar 

  3. Detterbeck F. What to do with “surprise” N2?: intraoperative Management of Patients with non-small cell lung Cancer. J Thorac Oncol. 2008;3(3):289–302.

    Article  Google Scholar 

  4. Ramnath N, Dilling TJ, Harris LJ, Kim AW, Michaud GC, Balekian AA, et al. Treatment of stage III non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2013;143(5, Supplement):e314S–e40S.

    Article  CAS  Google Scholar 

  5. Gospodarowicz MK, Brierley JD, Wittekind C. TNM classification of malignant tumours. Hoboken: Wiley; 2017.

    Google Scholar 

  6. Riquet M, Bagan P, Le Pimpec BF, Banu E, Scotte F, Foucault C, et al. Completely resected non-small cell lung cancer: reconsidering prognostic value and significance of N2 metastases. Ann Thorac Surg. 2007;84(6):1818–24.

    Article  Google Scholar 

  7. Veeramachaneni NK, Feins RH, Stephenson BJK, Edwards LJ, Fernandez FG. Management of stage IIIA non-small cell lung cancer by thoracic surgeons in North America. Ann Thorac Surg. 2012;94(3):922–8.

    Article  Google Scholar 

  8. Tanner NT, Gomez M, Rainwater C, Nietert PJ, Simon GR, Green MR, et al. Physician preferences for management of patients with stage IIIA NSCLC: impact of bulk of nodal disease on therapy selection. J Thorac Oncol. 2012;7(2):365–9.

    Article  Google Scholar 

  9. Albain KS, Swann RS, Rusch VW, Turrisi AT III, Shepherd FA, Smith C, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet. 2009;374(9687):379–86.

    Article  CAS  Google Scholar 

  10. Kang CH, Ra YJ, Kim YT, Jheon SH, Sung SW, Kim JH. The impact of multiple metastatic nodal stations on survival in patients with resectable N1 and N2 nonsmall-cell lung cancer. Ann Thorac Surg. 2008;86(4):1092–7.

    Article  Google Scholar 

  11. Andre F, Grunenwald D, Pignon JP, Dujon A, Pujol JL, Brichon PY, et al. Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. J Clin Oncol Off J Am Soc Clin Oncol. 2000;18(16):2981–9.

    Article  CAS  Google Scholar 

  12. Casali C, Stefani A, Natali P, Rossi G, Morandi U. Prognostic factors in surgically resected N2 non-small cell lung cancer: the importance of patterns of mediastinal lymph nodes metastases. Eur J Cardiothorac Surg. 2005;28(1):33–8.

    Article  Google Scholar 

  13. Pataer A, Kalhor N, Correa AM, Raso MG, Erasmus JJ, Kim ES, et al. Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy. J Thorac Oncol. 2012;7(5):825–32.

    Article  Google Scholar 

  14. Suntharalingam M, Paulus R, Edelman MJ, Krasna M, Burrows W, Gore E, et al. Radiation therapy oncology group protocol 02-29: a phase II trial of neoadjuvant therapy with concurrent chemotherapy and full-dose radiation therapy followed by surgical resection and consolidative therapy for locally advanced non-small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys. 2012;84(2):456–63.

    Article  Google Scholar 

  15. Chiou VL, Burotto M. Pseudoprogression and immune-related response in solid tumors. J Clin Oncol. 2015;33(31):3541–3.

    Article  CAS  Google Scholar 

  16. Depierre A, Milleron B, Moro-Sibilot D, Chevret S, Quoix E, Lebeau B, et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non–small-cell lung cancer. J Clin Oncol. 2002;20(1):247–53.

    PubMed  Google Scholar 

  17. Cerfolio RJ, Maniscalco L, Bryant AS. The treatment of patients with stage IIIA non-small cell lung cancer from N2 disease: who returns to the surgical arena and who survives. Ann Thorac Surg. 2008;86(3):912–20.

    Article  Google Scholar 

  18. van Meerbeeck JP, On behalf of the European Organisation for R, Treatment of Cancer-Lung Cancer G, Kramer GWPM, On behalf of the European Organisation for R, Treatment of Cancer-Lung Cancer G, et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non–small-cell lung cancer. J Natl cancer Inst. 2007;99(6):442–50.

  19. Kim AW, Boffa DJ, Wang Z, Detterbeck FC. An analysis, systematic review, and meta-analysis of the perioperative mortality after neoadjuvant therapy and pneumonectomy for non-small cell lung cancer. J Thorac Cardiovasc Surg. 2012;143(1):55–63.

    Article  Google Scholar 

  20. •• Pless M, Stupp R, Ris H-B, Stahel RA, Weder W, Thierstein S, et al. Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial. Lancet. 2015;386(9998):1049–56 Randomized controlled trial evaluating outcomes following sequential neoadjuvant chemotherapy and radiation or che-motherapy alone in patients with IIIA N2 NSCLC. There was no observed difference in median overall survival between groups.

    Article  Google Scholar 

  21. Cheung MC, Hamilton K, Sherman R, Byrne MM, Nguyen DM, Franceschi D, et al. Impact of teaching facility status and high-volume centers on outcomes for lung cancer resection: an examination of 13,469 surgical patients. Ann Surg Oncol. 2009;16(1):3–13.

    Article  Google Scholar 

  22. Group NM-aC. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet (London, England). 2014;383(9928):1561–71.

    Article  Google Scholar 

  23. Eberhardt WE, Pottgen C, Gauler TC, Friedel G, Veit S, Heinrich V, et al. Phase III study of surgery versus definitive concurrent chemoradiotherapy boost in patients with resectable stage IIIA(N2) and selected IIIB non-small-cell lung cancer after induction chemotherapy and concurrent chemoradiotherapy (ESPATUE). J Clin Oncol Off J Am Soc Clin Oncol. 2015;33(35):4194–201.

    Article  CAS  Google Scholar 

  24. Donington J, Paulus R, Edelman M, M K, Q L, M S, et al., editors. Safety and feasibility of lobectomy following concurrent chemotherapy and high dose radiation for IIIA NSCLC: pooled surgical results of NRG oncology RTOG 0229 and 039. American Association for Thoracic Surgery annual meeting; 2017; Boston, MA.

  25. Katakami N, Tada H, Mitsudomi T, Kudoh S, Senba H, Matsui K, et al. A phase 3 study of induction treatment with concurrent chemoradiotherapy versus chemotherapy before surgery in patients with pathologically confirmed N2 stage IIIA nonsmall cell lung cancer (WJTOG9903). Cancer. 2012;118(24):6126–35.

    Article  CAS  Google Scholar 

  26. Girard N, Mornex F, Douillard J-Y, Bossard N, Quoix E, Beckendorf V, et al. Is neoadjuvant chemoradiotherapy a feasible strategy for stage IIIA-N2 non-small cell lung cancer? Mature results of the randomized IFCT-0101 phase II trial. Lung Cancer (Amsterdam, Netherlands). 2010;69(1):86–93.

    Article  Google Scholar 

  27. Chen Y, Peng X, Zhou Y, Xia K, Zhuang W. Comparing the benefits of chemoradiotherapy and chemotherapy for resectable stage III A/N2 non-small cell lung cancer: a meta-analysis. World J Surg Oncol. 2018;16(1):8.

    Article  Google Scholar 

  28. Yang CF, Gulack BC, Gu L, Speicher PJ, Wang X, Harpole DH, et al. Adding radiation to induction chemotherapy does not improve survival of patients with operable clinical N2 non-small cell lung cancer. J Thorac Cardiovasc Surg. 2015;150(6):1484–92 discussion 92-3.

    Article  Google Scholar 

  29. Toyooka S, Kiura K, Shien K, Katsui K, Hotta K, Kanazawa S, et al. Induction chemoradiotherapy is superior to induction chemotherapy for the survival of non-small-cell lung cancer patients with pathological mediastinal lymph node metastasis. Interact Cardiovasc Thorac Surg. 2012;15(6):954–60.

    Article  Google Scholar 

  30. Higgins K, Chino JP, Marks LB, Ready N, D'Amico TA, Clough RW, et al. Preoperative chemotherapy versus preoperative chemoradiotherapy for stage III (N2) non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2009;75(5):1462–7.

    Article  CAS  Google Scholar 

  31. Thomas M, Rube C, Hoffknecht P, Macha HN, Freitag L, Linder A, et al. Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer. Lancet Oncol. 2008;9(7):636–48.

    Article  Google Scholar 

  32. Pezzetta E, Stupp R, Zouhair A, Guillou L, Taffe P, von Briel C, et al. Comparison of neoadjuvant cisplatin-based chemotherapy versus radiochemotherapy followed by resection for stage III (N2) NSCLC. Eur J Cardiothorac Surg. 2005;27(6):1092–8.

  33. Yang CF, Adil SM, Anderson KL, Meyerhoff RR, Turley RS, Hartwig MG, et al. Impact of patient selection and treatment strategies on outcomes after lobectomy for biopsy-proven stage IIIA pN2 non-small cell lung cancer. Eur J Cardiothorac Surg. 2016;49(6):1607–13.

    Article  Google Scholar 

  34. Moya-Horno I, Viteri S, Karachaliou N, Rosell R. Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC). Ther Adv Med Oncol. 2018;10:1758834017745012.

    Article  Google Scholar 

  35. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer. N Engl J Med. 2017;377(20):1919–29.

    Article  CAS  Google Scholar 

  36. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. New England Journal of Medicine. 2018.

  37. •• Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, et al. Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. N Engl J Med. 2018;378(21):1976–86. Initial prospective evaluation of neoadjuvant immunotherapy in resectable NSCLC., demonstrated safety and efficacy of this approach.

  38. • Broderick SR, Bott M, Park B, Isbell J, Adusumilli P. Operative Experience with Pulmonary Resection following Neoadjuvant Nivolumab in Patients with Resectable Non-small Cell Lung Cancer. American Association for Thoracic Surgery Annual Meeting; San Diego, CA 2018. Initial operative experience in patients with resectable stage I, II, or IIIA NSCLC who underwent neoadjuvant PD-1 blockade with nivolumab. There was no observed increase in perioperative morbidity or mortality.

  39. • Rusch VW, Chaft JE, Johnson B, Wistuba II, Kris MG, Lee JM, et al. Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Initial results from a multicenter study (LCMC3). J Clin Oncol. 2018;36(15_suppl):8541. Initial results from a large multicenter trial evaluating out-comes following neoadjuvant PD-L1 blockade with atezoli-zumab in patients with resectable stage IB to IIIB NSCLC. The authors found no delay in time to surgery, an acceptable side effect profile, and poor correlation between radiographic and pathologic response.

  40. Cascone T, William WN, Weissferdt A, Leung CH, Federico L, Haymaker C, et al. Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC). Munich: European Society for Medical Oncology; 2018.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, The University of Chicago Medicine and Biological Sciences, Chicago, IL, USA

    Darren S. Bryan MD

  2. Section of Thoracic Surgery, Department of Surgery, The University of Chicago Medicine and Biological Sciences, 5841 S. Maryland Ave, Chicago, IL, USA

    Jessica S. Donington MD, MSCR

Authors
  1. Darren S. Bryan MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jessica S. Donington MD, MSCR
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jessica S. Donington MD, MSCR.

Ethics declarations

Conflict of Interest

Darren S. Bryan declares that he has no conflict of interest.

Jessica S. Donington has received honoraria and reimbursement for travel expenses from AstraZeneca.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Lung Cancer

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bryan, D.S., Donington, J.S. The Role of Surgery in Management of Locally Advanced Non-Small Cell Lung Cancer. Curr. Treat. Options in Oncol. 20, 27 (2019). https://doi.org/10.1007/s11864-019-0624-7

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11864-019-0624-7

Keywords

Search

Navigation